• Why ChemoFx^®?
• Commitment to clinical proof
• ChemoFx^®
  clinical trials
• Indications & use
• Specimen handling
• Interpretation
  of results
• Precision Therapeutics
  Bibliography
• Take a
  Lab Tour

Treatment guidelines are a tool to help direct primary therapy for many types of cancer, but there are times when these guidelines fall short. What do you do in cases where patients are refractory to initial treatment, have rare tumor types or tumors with no established protocol, or suffer from recurrent cancer? At times like these, a drug response marker could provide a valuable edge in helping you to identify the treatment choices that are most likely to be effective for your particular cancer patient.

ChemoFx^® was created to help you rule out chemotherapies that don't work and focus on the ones that are more likely to work—reducing the risk of ineffective therapies which can lead to:^1-5

• Tumor progression
• Increased side effects
• Accumulated toxicity
• Development of cross-resistance
• Decreased efficacy of future treatments
• Decreased quality of life

Unlike other similar tests, ChemoFx^® measures both chemosensitivity and resistance. So you’ll be able to determine which chemotherapies are least likely to work for your individual patient, and which are most likely to work.

In addition to helping protect your patients from ineffective therapies, you also want to spare them from any unnecessary procedures. ChemoFx^® can help you accomplish both. The test requires a small tissue sample from surgery or as little as two core needle biopsies (≥35 mg) or ascites or pleural fluid (≥100 cc). This small sample size allows for less invasive procedures at multiple stages of care. And because cells grow and cycle in culture, ChemoFx^® ensures enrichment of relevant malignant cells for testing.

Results are provided within a typical time frame for initiating therapy,^12-14 enabling you to make crucial decisions without delaying treatment. So your patients can get on with their therapy—and more importantly, their lives.

No two cancer patients are the same. And neither is their response to chemotherapy. With ChemoFx^®, you can personalize your patient's treatment plan by testing multiple single agents or combination chemotherapies in the lab before choosing one for your cancer patient. Depending on the type of cancer and your patient's needs, you may also want to test various biologics.

Select up to 12 drugs or drug combinations, and use your experience and knowledge of each patient to choose a standard panel or design a custom panel. Keep in mind that choosing agents from different drug classes may help you evaluate alternative treatment options for your patients.